HAVCR2 and colorectal cancer: Colorectal cancer patients presented an enrichment of circulating Treg cells, where the LAG-3+TIM-3+ subset exhibited stronger expression of inhibitory molecules, and LAG-3+TIM-3+ Treg cells could inhibit pro-inflammatory macrophage activation [72].